ASX · PTX.AX
Prescient Therapeutics Limited
A$0.05-A$0.00 (-2.73%)
Prescient Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 56.8% below the high.
Loading market information…
ASX · ATX.AX · AUD
Stock price, earnings
Quote as of Oct 30, 2026, 02:23 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Amplia Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 68.36% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Amplia Therapeutics Limited’s next earnings report is currently expected on Nov 27, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Amplia Therapeutics Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:57 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.05-A$0.00 (-2.73%)
Prescient Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 56.8% below the high.
A$0.26+A$0.01 (+2.0%)
Mach7 Technologies Limited’s quoted price sits in the lower half of its reported 52-week range, 62.77% below the high.
A$0.44+A$0.05 (+12.99%)
Cyclopharm Limited’s quoted price sits in the lower half of its reported 52-week range, 66.28% below the high.
A$0.04-A$0.00 (-5.13%)
Micro-X Limited’s quoted price sits in the lower half of its reported 52-week range, 67.83% below the high.
A$0.07A$0.00 (0.0%)
Beamtree Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 68.44% below the high.
A$0.12+A$0.00 (+2.56%)
Proteomics International Laboratories Ltd.’s quoted price sits in the lower half of its reported 52-week range, 86.05% below the high.
A$0.08-A$0.00 (-1.27%)
Genetic Signatures Limited’s quoted price sits in the lower half of its reported 52-week range, 77.39% below the high.
A$0.00-A$0.00 (-11.11%)
ImpediMed Limited’s quoted price sits in the lower half of its reported 52-week range, 90.48% below the high.
